<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02327845</url>
  </required_header>
  <id_info>
    <org_study_id>20160603</org_study_id>
    <secondary_id>U54NS092091</secondary_id>
    <nct_id>NCT02327845</nct_id>
  </id_info>
  <brief_title>Phenotype, Genotype &amp; Biomarkers in ALS and Related Disorders</brief_title>
  <official_title>Phenotype, Genotype &amp; Biomarkers in ALS and Related Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Advancing Translational Science (NCATS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Jude Children's Research Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ALS Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goals of this study are: (1) to better understand the relationship between the phenotype
      and genotype of amyotrophic lateral sclerosis (ALS) and related diseases, including primary
      lateral sclerosis (PLS), hereditary spastic paraplegia (HSP), progressive muscular atrophy
      (PMA), and frontotemporal dementia (FTD); and (2) to develop biomarkers that might be useful
      in aiding therapy development for this group of disorders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will recruit patients with ALS, ALS-FTD, PLS, HSP, and PMA, with a focus on
      incident cases. Patients with both familial and sporadic forms of these diseases will be
      enrolled and followed longitudinally using a standardized set of evaluations. Biological
      samples (blood, urine, CSF) will be collected from all study participants, and will be used
      for biomarker discovery and validation. Family members of affected individuals may also be
      enrolled and asked to contribute DNA and biological samples to aid genetic and biomarker
      discovery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Phenotypic correlates of genotype</measure>
    <time_frame>24 months</time_frame>
    <description>Using longitudinally collected deep phenotypic data, this project aims to define the natural history (i.e. temporal rate of disease progression) of the motor and frontotemporal system (behavior, cognition and language) phenotypes of ALS and related disorders in patients with identifiable genetic mutations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Genetic determinants of phenotype</measure>
    <time_frame>24 months</time_frame>
    <description>By combining longitudinally collected deep phenotypic data with deep genetic data (e.g. whole exome or whole genome sequencing), this project aims to define genetic variants that are associated with identifiable phenotypic features in patients with ALS and related disorders.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Biomarkers</measure>
    <time_frame>24 months</time_frame>
    <description>Biomarkers relevant to therapeutic development</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <condition>Frontotemporal Dementia</condition>
  <condition>Primary Lateral Sclerosis</condition>
  <condition>Hereditary Spastic Paraplegia</condition>
  <condition>Progressive Muscular Atrophy</condition>
  <condition>Multisystem Proteinopathy</condition>
  <arm_group>
    <arm_group_label>Affected</arm_group_label>
    <description>Affected with any of the diseases that are the focus of study by the CReATe Consortium, including ALS, ALS-FTD, HSP, PLS, PMA and MSP.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Unaffected</arm_group_label>
    <description>Unaffected family members of enrolled affected individuals.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA, serum, urine and CSF
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with ALS or a related neurodegenerative disorder, including FTD, HSP, PLS, PMA and
        MSP. Select family members of affected participants.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Member of at least one of the following categories:

               1. Individuals with a clinical diagnosis of ALS or a related disorder, including
                  FTD, HSP, PLS, PMA and MSP (sporadic or familial).

               2. Family member of an enrolled affected individual.

          -  Able and willing to comply with relevant procedures.

        Exclusion Criteria:

          -  Affected with end or late stage disease.

          -  A condition or situation which, in the PI's opinion, could confound the study finding
             or may interfere significantly with the individual's participation and compliance with
             the study protocol. This includes (but is not limited to) neurological, psychological
             and/or medical conditions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Benatar, DPhil</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Benatar, DPhil</last_name>
    <phone>305-243-4015</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sumaira Hussain</last_name>
    <phone>1-844-837-1031</phone>
    <email>projectcreate@med.miami.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California San Diego (UCSD)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center (CPMC)</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Hernandez</last_name>
      <phone>305-243-2345</phone>
      <email>projectcreate@miami.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Benatar, MBChB, MS, DPhil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kansas University Medical Center (KUMC)</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hellen Tanui</last_name>
      <phone>913-945-9934</phone>
      <email>htanui@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Richard Barohn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Twin Cities ALS Research Consortium</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Rosario</last_name>
      <phone>215-898-3081</phone>
      <email>luis.rosario@pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Corey McMillan, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern (UTSW)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center San Antonio (UTHSCSA)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Virginia (UVA)</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eberhard Karls University of Tübingen</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Cape Town</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 24, 2014</study_first_submitted>
  <study_first_submitted_qc>December 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2014</study_first_posted>
  <last_update_submitted>June 5, 2020</last_update_submitted>
  <last_update_submitted_qc>June 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Michael Benatar</investigator_full_name>
    <investigator_title>Chief of the Neuromuscular Division, Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>natural history, biomarkers, phenotype, genotype</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
    <mesh_term>Paraplegia</mesh_term>
    <mesh_term>Spastic Paraplegia, Hereditary</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

